ITCI Intra-Cellular: Enterprise Value-to-Revenue Ratio

Intra-Cellular Therapies (ITCI) has fully outsourced the production of Caplyta while maintaining control over its patents. The enterprise value-to-revenue ratio visualizes the market valuation excluding debt, where reflects the latest value of the metric. Geopolitics complicates raw material logistics and the registration of new drugs, yet sales expansion in depression treatment ensures a steady influx of patients.
ITCI (Intra-Cellular Therapies, Inc.): analytical breakdowns and indicator data

To filter for high-quality assets, investors utilize multiples that exclude the impact of leverage on market capitalization. This metric measures business value via the sum of equity and net debt relative to sales volume, allowing for an assessment of the commercialization efficiency of Intra-Cellular Therapies (ITCI) innovative drugs for the treatment of psychiatric disorders by analyzing the EV/Sales ratio as an indicator of market consensus.